Cargando…

Combination of Complement-Dependent Cytotoxicity and Relative Fluorescent Quantification of HLA Length Polymorphisms Facilitates the Detection of a Loss of Heterozygosity

Loss of heterozygosity (LOH) is a common event in malignant cells. In this work we introduce a new approach to identify patients with loss of heterozygosity in the HLA region either at first diagnosis or after HLA mismatched allogeneic HSCT. Diagnosis of LOH requires a high purity of recipient targe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Witter, Klaus, Reibke, Roland, Subklewe, Marion, Zahn, Robert, Kauke, Teresa, Spiekermann, Karsten, Spannagl, Michael, Tischer, Johanna, Hiddemann, Wolfgang, Dick, Andrea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3996364/ https://www.ncbi.nlm.nih.gov/pubmed/24860670 http://dx.doi.org/10.1155/2014/541345

Ejemplares similares

Impact of extramedullary disease in AML patients undergoing sequential RIC for HLA-matched transplantation: occurrence, risk factors, relapse patterns, and outcome
por: Fraccaroli, Alessia, et al.
Publicado: (2023)

Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab
por: Köhnke, Thomas, et al.
Publicado: (2015)

The Role of Therapeutic Leukapheresis in Hyperleukocytotic AML
por: Pastore, Friederike, et al.
Publicado: (2014)

Impressive thrombocytosis evolving in a patient with a BCR-ABL positive CML in major molecular response during dasatinib treatment unmasks an additional JAK2V617F
por: Pastore, Friederike, et al.
Publicado: (2013)

Immunotherapy using bispecific T cell engager (BiTE(®)) antibodies: preclinical and clinical experience in acute leukemia
por: Subklewe, Marion, et al.
Publicado: (2014)

Nonspecific complement activation by streptococcal structures. I. Re- evaluation of HLA cytotoxicity inhibition
Publicado: (1976)

Insignificant effects of loss of heterozygosity in HLA in the efficacy of immune checkpoint blockade treatment
por: Yang, Yohan, et al.
Publicado: (2022)

Activating FLT3 Mutants Show Distinct Gain-of-Function Phenotypes In Vitro and a Characteristic Signaling Pathway Profile Associated with Prognosis in Acute Myeloid Leukemia
por: Janke, Hanna, et al.
Publicado: (2014)

HLA Class I and II alleles, heterozygosity and HLA-KIR interactions are associated with rates of genital HSV shedding and lesions
por: Magaret, Amalia, et al.
Publicado: (2016)

Frequency of hematologic and solid malignancies in the family history of 50 patients with acute myeloid leukemia – a single center analysis
por: Sandner, Anne-Sophie, et al.
Publicado: (2019)

An Advanced Preclinical Mouse Model for Acute Myeloid Leukemia Using Patients' Cells of Various Genetic Subgroups and In Vivo Bioluminescence Imaging
por: Vick, Binje, et al.
Publicado: (2015)

Outcome after Desensitization in HLA or ABO-Incompatible Kidney Transplant Recipients: A Single Center Experience
por: Kauke, Teresa, et al.
Publicado: (2016)

CD86 and IL-12p70 Are Key Players for T Helper 1 Polarization and Natural Killer Cell Activation by Toll-Like Receptor-Induced Dendritic Cells
por: Lichtenegger, Felix S., et al.
Publicado: (2012)

A 29-gene and cytogenetic score for the prediction of resistance to induction treatment in acute myeloid leukemia
por: Herold, Tobias, et al.
Publicado: (2018)

Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia
por: Rothenberg-Thurley, Maja, et al.
Publicado: (2018)

A new method to detect loss of heterozygosity using cohort heterozygosity comparisons
por: Green, Michael R, et al.
Publicado: (2010)

T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment
por: Schnorfeil, Frauke M., et al.
Publicado: (2015)

Assessment of Heterozygosity and Genome-Wide Analysis of Heterozygosity Regions in Two Duroc Pig Populations
por: Ruan, Donglin, et al.
Publicado: (2022)

Clinical Characteristics and Outcome Analysis for HLA Loss Patients Following Partially Mismatched Related Donor Transplantation Using HLA Chimerism for Loss of Heterozygosity Analysis by Next-Generation Sequencing
por: Wang, Andi, et al.
Publicado: (2022)

INTRARENAL COMPLEMENT FIXATION BY CYTOTOXIC ANTIBODIES
por: Sellin, D., et al.
Publicado: (1970)

Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged 75 years or older
por: Prassek, Victoria V., et al.
Publicado: (2018)

Complement Binding Anti-HLA Antibodies and the Survival of Kidney Transplantation
por: Muñoz-Herrera, Claudia M., et al.
Publicado: (2023)

Loss of heterozygosity: what is it good for?
por: Ryland, Georgina L., et al.
Publicado: (2015)

Treatment, outcome and re-vaccination of patients with SARS-CoV-2 vaccine-associated immune thrombocytopenia
por: Ruzicka, Michael, et al.
Publicado: (2022)

Effect of Apheresis for ABO and HLA Desensitization on Anti-Measles Antibody Titers in Renal Transplantation
por: Schönermarck, Ulf, et al.
Publicado: (2011)

NBS1 Heterozygosity and Cancer Risk
por: di Masi, Alessandra, et al.
Publicado: (2008)

Loss of Heterozygosity and Its Importance in Evolution
por: Smukowski Heil, Caiti
Publicado: (2023)

Lack of adalimumab's complement dependent cytotoxicity on human cells expressing complement regulatory proteins
por: Grebe, K M, et al.
Publicado: (2010)

Conjunctival Scarring in Trachoma Is Associated with the HLA-C Ligand of KIR and Is Exacerbated by Heterozygosity at KIR2DL2/KIR2DL3
por: Roberts, Chrissy h., et al.
Publicado: (2014)

HLA-C*04:01 Affects HLA Class I Heterozygosity and Predicted Affinity to SARS-CoV-2 Peptides, and in Combination With Age and Sex of Armenian Patients Contributes to COVID-19 Severity
por: Hovhannisyan, Anahit, et al.
Publicado: (2022)

Toll‐like receptor 7/8‐matured RNA‐transduced dendritic cells as post‐remission therapy in acute myeloid leukaemia: results of a phase I trial
por: Lichtenegger, Felix S, et al.
Publicado: (2020)

P20. Lack of T cell exhaustion in acute myeloid leukaemia
por: Schnorfeil, FM, et al.
Publicado: (2014)

Current status of immunotherapy in acute myeloid leukemia
por: Subklewe, Marion
Publicado: (2018)

Loss of heterozygosity of TRIM3 in malignant gliomas
por: Boulay, Jean-Louis, et al.
Publicado: (2009)

The Population Growth Consequences of Variation in Individual Heterozygosity
por: Di Fonzo, Martina M. I., et al.
Publicado: (2011)

Allelic sequence heterozygosity in single Giardia parasites
por: Ankarklev, Johan, et al.
Publicado: (2012)

Analysis of Loss of Heterozygosity in Korean Patients with Keratoacanthoma
por: Ha, Tae-Won, et al.
Publicado: (2005)

Effects of heterozygosity on performance of purebred and crossbred pigs
por: Iversen, Maja Winther, et al.
Publicado: (2019)

Heterozygosity mapping for human dominant trait variants
por: Imai‐Okazaki, Atsuko, et al.
Publicado: (2019)

Loss of Heterozygosity Drives Adaptation in Hybrid Yeast
por: Smukowski Heil, Caiti S., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_bnl27mru35cskqr73bjidia6ed